News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012


2/28/2012 10:37:51 AM

SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release its unaudited financial results for the fourth quarter and full year ended December 31, 2011 on March 12, 2012. Management will host a conference call to discuss the results at 08:00AM New York Time on March 12, 2012 (08:00PM Beijing Time on March 12, 2012).

Conference Call

Mr. Michael Xin Hui, founder and Chief Executive Officer; Mr. William Dai, Chief Financial Officer; and Ms. Lan Xie, Vice President of Finance and Investor Relations, will discuss the results and take questions following the prepared remarks.

Dial-in details for the live conference call are as follows:

International: +1-718-354-1231
United States: +1-866-519-4004
United Kingdom: 080-8234-6646
Hong Kong: +852-2475-0994

Passcode: SHP

A live webcast of the conference call will be available on the investor relations section of the Company's website at: http://www.shangpharma.com.

A telephone replay of the call will be available for seven days from March 13, 2012, 11:00AM U.S. Eastern Time to March 20, 2012, 11:59PM U.S. Eastern Time. The dial-in details for the replay are as follows:

International: +61-2-8235-5000
Passcode: 57079920

ABOUT SHANGPHARMA CORPORATION

ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

For further information, please contact:

ShangPharma
Ms. Lan Xie
Vice President of Finance and Investor Relations
Email: ir@shangpharma.com

Brunswick Group
Josh Gartner
Email: shangpharma@brunswickgroup.com
Phone: 86-10-5960-8600

SOURCE ShangPharma Corporation


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES